Rho(D) immune globulin
Clinical data | |
---|---|
Trade names | WinRho, RhoGAM, others: |
Other names | Rh0(D) immune globulin, anti-D (Rh0) immunoglobulin, immunoglobulinum humanum anti–D |
AHFS/Drugs.com | Monograph |
Pregnancy category |
|
Routes of administration | Intramuscular injection |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
ChemSpider |
|
(what is this?) (verify) |
Rho(D) immune globulin (RhIG) is a medication used to prevent
Common side effects include
Rho(D) immune globulin came into medical use in the 1960s,
RhIG is on the World Health Organization's List of Essential Medicines.[6][7]
Medical uses
Prevention of alloimmunization
Alloimmunization: mechanism, timing
Even in normal pregnancies, a small number of fetal blood cells enters the maternal bloodstream (fetomaternal hemorrhage). If a mother is RhD negative, but the fetus is RhD positive, the mother's immune system may develop an immune response (develops
The RhD status of the fetus is determined by genetic inheritance. In a pregnancy where the mother is RhD negative and the father is RhD positive, the probability of the fetus having RhD positive blood is dependent on whether the father is
Exposure to fetal blood cells that can cause RhD alloimmunization can happen during normal pregnancy and delivery, miscarriage, amniocentesis, cordocentesis, chorionic villus sampling, external cephalic version, trauma.[3][8] 92% of women who develop an anti-D during pregnancy do so at or after 28 weeks gestation.[10][9][11]
In an RhD negative mother, RhIG can temporarily prevent sensitization of the maternal immune system to RhD
Recommendations for use
The
RhIG is recommended in the UK after antenatal pathological events that are likely to cause a feto–maternal hemorrhage. Applicable 'pathologic events' include accidents that may induce fetomaternal hemorrhage (motor vehicle accidents, falls, abdominal trauma), following obstetric/gynecologic procedures during pregnancy, and at the time of threatened- or spontaneous-/elective abortions, regardless of gestational age. RhIG is also recommended after normal delivery, with amounts detailed in the next section.[12]
There is insufficient evidence that the use of Rho(D) immune globulin after a spontaneous miscarriage is needed and a
Rh immune globulin is composed of IgG antibodies and therefore is able to cross the placenta. In rare cases this can cause a baby to have a weakly positive
Following delivery
Widespread use of RhIG started with postpartum administration, as delivery is the main source of significant fetomaternal hemorrhage. A D-negative mother who is not alloimmunized to D should also receive an appropriate dose of RhIG after delivery of a D-positive infant. (In older recommendations, the Rh status of the infant is only known at delivery from testing of cord blood.)[9] If the infant is D-positive, the mother should have a postpartum blood sample screened for fetomaternal hemorrhage in order to determine the appropriate dosage of RhIG to be administered. (The presence of residual anti-D from antepartum RhIG administration does not indicate ongoing protection from alloimmunization – repeat administration of RhIG is necessary.)[12]
The
Postpartum RhIG should be administered within 72 hours of delivery. If prophylaxis is delayed, the likelihood that alloimmunization will be prevented is decreased. However, ACOG still recommends that RhIG be administered because partial protection still occurs.[10][11] If the D-type of a newborn or stillborn is unknown or cannot be determined, RhIG should be administered.
Immune thrombocytopenia
Primary
Contraindications
The following females are not candidates for RhIG:
- D-negative females whose fetus is known to be D-negative
- D-negative females who have been previously alloimmunized to D (they have already formed an anti-D alloantibody)
- Any D-positive females
- Women who test positive for one of the weak D mutations by molecular testing should be considered RhD positive and not receive RhIG[21]
- Women who test positive for one of the partial D mutations (by molecular testing) should be treated as RhD negative and receive RhIG as clinically indicated[21]
History
The first Rho(D) immune globulin treatment "skymed" was introduced by Ortho Clinical Diagnostics, a subsidiary holding of Jskymed, and was first administered on May 29, 1968, to Marianne Cummins in Teaneck, New Jersey.[22]
In 1996, ZLB Bioplasma (part of CSL Behring) was given approval to sell Rhophylac in Europe. Effectiveness was demonstrated in a clinical trial in 2003 and in 2004 Rhophylac was approved in the United States.[23]
Society and culture
Manufacturing and safety
Human plasma
Conventional Rho(D) immune globulin is extracted from human blood plasma. Excluding autoimmunity, only people who are themselves Rho(D) negative can make the anti-D antibody. As a result, there is a limited pool of people from which to draw plasma that can contain the desired IgG. Special anti-D donation programs are set up to account for this rarity.[24] Volunteers are given an injection containing the D antigen in order to make their immune system start producing the antibody (alloimmunization) or to boost the amounts. Only men and women who have no ability to become pregnant may apply.[25]
The most common way anti-D products are manufactured is by a form of the
Cell culture
There has been continual attempts to produce a monoclonal anti-D IgG formulation suitable for replacing the current polyclonal formulation.[28] A monoclonal antibody can be produced without requiring human donors (and associated supply and disease risks) and would be more consistent from batch to batch.[8]
India has approved a monoclonal formulation called Rhoclone (Bharat Serums and Vaccines Ltd.),
Roledumab and Rozrolimupab are two other formulations that have undergone some clinical trials. The former is a monoclonal IgG. The latter is a recombinant mixture of 25 IgGs.[8]
Routes of administration
RhIG can be administered by either intramuscular (IM) or intravenous (IV) injection, depending on the preparation. The IM-only preparation should never be administered IV due to the risk of complement system activation. Multiple IM doses should be given at different sites or at different times within the 72-hour window. Or, multiple IV doses can be administered according to the instructions in the package insert.[citation needed]
Names
Rho(D) immune globulin is also spelled Rh0(D) immune globulin (letter
Rhophylac is manufactured by CSL Limited. RhoGAM and MICRhoGam are brand names of Kedrion Biopharma. Other brand names are BayRHo-D, Gamulin Rh, HypRho-D Mini-Dose, Mini-Gamulin Rh, Partobulin SDF (Baxter), Rhesonativ (Octapharma), and RhesuGam (NBI). KamRho-D I.M. is a brand name of Kamada Ltd.
The United States
See also
- Rhesus blood group system
- Blood types
- Immunology
- Rh disease
- John Gorman (physician)
- James Harrison (blood donor) – prolific anti-D donor
References
- FDA. Retrieved 22 Oct 2023.
- ^ a b c d e f g h i j k "Rho(D) Immune Globulin". Drugs.com. The American Society of Health-System Pharmacists. Archived from the original on 9 January 2017. Retrieved 8 January 2017.
- ^ ISBN 9780857111562.
- OCLC 968617246– via Google Books.
- ^ Probyn A (2022-11-01). "A vial of human serum, an ice box and an illegal flight: how an Australian doctor saved millions of babies' lives". ABC News. Retrieved 2022-11-02.
- hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
- ^ S2CID 26083215.
- ^ PMID 2856526.
- ^ ISBN 978-1-56395-260-9.
- ^ a b Prevention of Rh D Alloimmunization. ACOG Practice Bulletin (Report). Washington, DC: American College of Obstetricians and Gynecologists. 1999.
- ^ a b c "Use of Anti-D Immunoglobulin for Rh Prophylaxis". Royal College of Obstetricians and Gynaecologists. May 2002. Archived from the original on 2008-12-30.
- PMID 2982267.
- National Institute for Health and Clinical Excellence. May 2002. Archivedfrom the original on 2008-08-28.
- PMID 23543581.
- ISBN 9780721603841.
- ^ Klein H, Anstee DJ (2005). "Haemolytic Disease of the Fetus and Newborn.". Mollison's Blood Transfusion in Clinical Medicine (11th ed.). Oxford: Blackwell. pp. 496–545.
- ^ PMID 19846889.
- ^ a b "Winrho SDF prescribing information" (PDF). www.winrho.com.
- S2CID 12375241.
- ^ S2CID 586699.
- ^ "RhoGAM product label, includes clinical trial data and prescribing information" (PDF). rhogam.com.
- ^ "History of HDN Treatment". CSL Behring. Archived from the original on 2008-11-21.
- ^ "Anti-D donor Steve Gansberg is just happy to help". Lifeblood.com.au. 9 June 2022.
- ^ "Anti-D: Rh-negative Plasma Donation". CSL Plasma.
- ^ "ChromaPlus Manufacturing Process". rhophylac.com. Archived from the original on 2008-11-21.
- ^ "RhoGAM Ultra-Filtered PLUS Rho(D) Immune Globulin (Human) Information Site". Johnson & Johnson Services, Inc. Archived from the original on 2006-03-11.
- PMID 16580863.
- PMID 31598044.
- PMID 32489976.
- ^ Staff (5 May 2010). "Cangene assumes U.S. commercialization rights for WinRho SDF". Biotech Week. United States. Archived from the original on 29 March 2015. Retrieved 28 December 2014.
- ^ Cash M (16 June 2010). "Cangene Corp. begins transformation project". Winnipeg Free Press. Archived from the original on 29 March 2015. Retrieved 28 December 2014.
External links
- Rho(D)+Immune+Globulin at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
- "Rho(D) Immune Globulin". Drug Information Portal. U.S. National Library of Medicine.